PATENT ABSTRACTS 211

clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.

5190756

M E T H O D S AND M A T E R I A I ~ F O R E X P R E S S I O N O F H U M A N P L A S M I N O G E N VARIANT

of TGF alpha in a subset of such neoplastic tis- sue which comprises contacting the tissue sec- tions with an antibody directed to an epitop¢ on TGF alpha under conditions such that the anti- body binds to the tissue sections detecting the antibody bound to the tissue sections and thereby detecting TGF alpha in the tissue sec- tions. The invention further provides the mono- clonal antibody 134A-2B3 (ATCC No. HB9993). Additionally, the invention concerns the monoclonal antibody 137-178 (ATCC No. HB9994).

Francis J Castellino, Deborah L Higgins as- signed to Genentech Inc

A cleavage-resistant plasminogen molecule is provided that is conveniently produced in recombinant cells by expression of a nucleic acid sequence encoding the plasminogen molecule. Preferably the plasminogen is a sequence variant with a modification in its two-chain cleavage site. The plasminogen molecule may be purified, acylated, complexed with acylated or non- acylated fibrinolytic enzymes, and formulated into pharmaceutical compositions for use in thrombolytic therapy.

5190858

M O N O C L O N A L ANTIBODIES D I R E C T E D TO E P I T O P E S OF

H U M A N T R A N S F O R M I N G G R O W T H FAC TOR- A L P H A AND

U S E S T H E R E O F

John M SorviUo, David M Valenzucla, Frederick H Reynolds, Port Coquitlam, as- signed to Oncogene Science Inc

The present invention provides a monoclonal antibody which specifically forms a complex with TGF alpha in formalin-fixed, paratiin- embedded tissue sections which has an affinity of a least 107, and which is directed to the epitope tO which monoclonal antibody 213-4.4 (ATCC No. HB9992) is directed. The invention further pro- rides the above-described monoclonal antibody wherein the epitope consists essentially of amino acids 34-43 of TGF alpha. Additionally, the in- vention concerns the monoclonal antibody 213- 4.4 (ATCC No. HB9992). The invention also provides a method of detecting TGF alpha in tis- sue sections of a tissue in which normal tissue is characterized by the absence of TGF alpha and neoplastic tissue is characterized by the presence

5190860

D I F F E R E N T I A L D I A G N O S T I C ASSAY F O R B R U C E L L O S I S

Leslie G Adams, Roger Smith, Joe W Tem- pleton, Kathleen Overholt, Port Coquitlam, as- signed to The Texas A & M University System

An immnnoassay procedure is provided which exhibits increased specificity over current pro- cedures. The procedure allows the differentia- tion of animals infected with Brucella abortus from animals vaccinated with Brucella abortus Strain 19. The invention employs unique mono- specific monoclonal antibodies having par- ticular affinity, specificity and binding characteristics directed to a B. abortus lipopolysaccharide antigen. The invention also concerns continuous hybrid cell lines for pro- ducing the unique monoclonai antibodies.

5190861

M E T H O D F O R T H E D I A G N O S I S O F R H E U M A T O I D ARTHRITIS

Taro Hayakawa, Shuji Kodama, Kazushi Iwata, Junichi Kishi, Kyoko Yamashita, Hisashi Iwata, Port Coquitlam assigned to Fuji Yakuhin

Kogyo Kabushiki Kaisha

A method for diagnosing rheumatoid arthritis, which is characterized by enzyme- immunologicaily measuring the amount of col- lagenasc inhibitor present in sera, plasmas or synovial fluids by way of a sandwich assay wherein two different monoclonal antibodies which specifically bind to different antigenic determinants of the collagenase inhibitor are used, and comparing the measured amount with that for normal subjects.